Boston Scientific (BSX) +5.6% premarket following its Q1 EPS beat and after it gives Q2 guidance...


Boston Scientific (BSX) +5.6% premarket following its Q1 EPS beat and after it gives Q2 guidance of $0.14-$0.17 vs. consensus of $0.10. Boston also expects revenue of $1.85B-$1.95B vs. $1.9B forecasts. Q1 net profit surged over threefold to $113M due to fewer one-time items.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs